Whalesbook
Chalo, pehle China ki baat karte hain. Pichhle 7 saalon mein, China ne biologics mein jo speed pakdi hai, woh dekhne layak hai. Sabse bada reason hai government ka solid support aur approval process ka ekdum fast hona. 2015 mein jahan sirf 9% new drug approvals biologics the, wahi 2023 tak yeh 42% ho gaya! 2024 mein toh inone 83 new drugs approve kiye, jo America ke 50 se kaafi zyada hain. Is speed ki wajah se, US ki biotech companies bhi ab inke saath kaam karna pasand kar rahi hain.
Ab aao apni story pe. India ke pharma companies ke liye generics mein success ke baad biologics ka market (jo 2034 tak $232 billion ka ho jayega) ek alag hi challenge hai. Generics toh low cost aur large scale manufacturing se ho gaya tha, par biologics ke liye advanced R&D, complex manufacturing aur super skilled log chahiye. Yahan humare paas abhi bhi tech, R&D, IP (Intellectual Property) aur US market access mein kaafi gaps hain. Experts keh rahe hain ki humein sirf cost-efficiency se aage badhkar 'capability leadership' dikhani hogi.
Agar companies ki valuations dekhein, toh China ki WuXi Biologics ka market cap around $129.75 billion tha. Hamari Biocon ka P/E ratio 78.28 aur market cap $584.07 billion tha March 2026 tak. Dr. Reddy's Laboratories ka P/E ratio 18.41 ke aas-paas hai March 2026 tak. Global biosimilars market toh $1.3 trillion tak ja sakta hai 2032 tak, aur India ka export $0.8 billion se $4.2 billion tak ho sakta hai 2030 tak. Par China ka aggressive approach aur R&D investment ek bada threat hai. Humare liye cell line engineering, IP strategy, aur US market mein entry ke challenges alag hain. Plus, geopolitical shifts mein 'China Plus One' strategy ke bawajood, humein abhi bhi bahot investment aur strategy change karni hogi. Agar yeh gaps nahi bhare toh hum pichhad jayenge.
Aage kya karna chahiye? Industry experts keh rahe hain ki India ko sirf products par focus karne ke bajaye innovation platforms, AI aur strong R&D ko jodna hoga. Drug discovery, AI aur manufacturing ko ek saath la kar repeatable platforms banana padega. Agar yeh bada shift nahi kiya, toh hum is global biologics race mein piche reh jayenge. Socho, future innovation isi mein hai, humein bhi iske liye ready hona hoga!